## Neo-adjuvant/Adjuvant Trials

### Neo-adjuvant Pembro for Stage III Melanoma

**UPC09618**
- **PI:** Dr. Giorgos Karakousis
- **Study Team:** PCAM; MD Anderson; University of Louisville
- **Key Eligibility & Screening:**
  - Clinical stage IIB/C resectable melanoma
  - Uveal or mucosal melanoma not eligible
  - No other active malignancy except treated cutaneous SCC, BCC or carcinoma in situ
  - No active autoimmune disease requiring systemic treatment in prior 3 months
  - Clinical stage III resectable melanoma
  - Uveal or mucosal melanoma not eligible
  - No other active malignancy except treated cutaneous SCC, BCC or carcinoma in situ
  - No active autoimmune disease requiring systemic treatment in prior 3 months
  - Baseline research bx, if feasible
  - Brain MRI at screening required
- **Treatment Arms:**
  - Arm A: If Path CR/near CR, then 1 yr adjuvant nivo
  - Arm B: If Path CR/near CR, then 1 yr adjuvant ipi/nivo x4 + nivo 1 yr
  - Arm C: If Path CR/near CR, then 1 yr adjuvant ipi/nivo x4 + nivo 1 yr

### Neo-adjuvant Nivo for Stage III Melanoma

**UPC02619**
- **PI:** Dr. Tara Mitchell
- **Study Team:** PCAM; Valley Forge; Lancaster General Health; Duke University
- **Key Eligibility & Screening:**
  - Clinical stage III resectable melanoma
  - Uveal or mucosal melanoma not eligible
  - No other active malignancy except treated cutaneous SCC, BCC or carcinoma in situ
  - No active autoimmune disease requiring systemic treatment in prior 3 months
  - Baseline research bx, if feasible
  - Brain MRI at screening required
- **Treatment Arms:**
  - Arm A: If Path CR/near CR, then 1 yr adjuvant nivo
  - Arm B: If Path CR/near CR, then 1 yr adjuvant nivo
  - Arm C: If Path CR/near CR, then 1 yr adjuvant ipi/nivo x4 + nivo 1 yr

### Neo-adjuvant Pembro for Merkel Cell Carcinoma

**UPC01623**
- **PI:** Dr. John Miura
- **Study Team:** PCAM
- **Key Eligibility & Screening:**
  - Surgically resectable stage IB, IC, III, or IV cutaneous melanoma
  - Uveal or mucosal melanoma not eligible
  - No prior systemic therapy or cancer vaccine
  - No evidence of disease at time of treatment start
  - No current or prior metastatic cancer
  - ECOG PS 0 or 1
  - No prior systemic anti-cancer immunotherapy for cSCC
  - Histologically confirmed metastatic melanoma (includes CNS mets)
  - ≥ 2 measurable lesions per RECIST 1.1
  - Prior adjuvant αPD-1 allowed (4 wk washout)
  - Prior adjuvant αCTLA4 excluded
  - CNS mets – symptomatic or require urgent local therapy are excluded
- **Treatment Arms:**
  - Arm A: If Path CR/near CR, then 1 yr adjuvant ipi/nivo
  - Arm B: If Path CR/near CR, then 1 yr adjuvant ipi/nivo x4 + nivo 1 yr

### Adjuvant mRNA vaccine for Melanoma

**UPC03623**
- **PI:** Dr. Ravi Amarawdi
- **Study Team:** PCAM
- **Key Eligibility & Screening:**
  - Pathologic resected stage IIIB, IIIC, IIID, or IV cutaneous melanoma
  - Uveal or mucosal melanoma not eligible
  - No prior systemic therapy or cancer vaccine
  - No evidence of disease at time of treatment start
  - No current or prior metastatic cancer
  - ECOG PS 0 or 1
  - No prior systemic anti-cancer immunotherapy for cSCC
  - Histologically confirmed metastatic melanoma (includes CNS mets)
  - ≥ 2 measurable lesions per RECIST 1.1
  - Prior adjuvant αPD-1 allowed (4 wk washout)
  - Prior adjuvant αCTLA4 excluded
  - CNS mets – symptomatic or require urgent local therapy are excluded
- **Treatment Arms:**
  - Arm A: Ipi/Nivo + mRNA vaccine q3wks for 9 cycles
  - Arm B: Pembro + placebo vaccine q3wks for 9 cycles

### Adjuvant Cemiplimab for SCC

**UPC04619**
- **PI:** Dr. Joanna Walker
- **Study Team:** PCAM
- **Key Eligibility & Screening:**
  - Histologically confirmed metastatic melanoma (includes CNS mets)
  - ≥ 2 measurable lesions per RECIST 1.1
  - Prior adjuvant αPD-1 allowed (4 wk washout)
  - Prior adjuvant αCTLA4 excluded
  - CNS mets – symptomatic or require urgent local therapy are excluded
- **Treatment Arms:**
  - Arm A: If Path CR/near CR, then 1 yr adjuvant nivo
  - Arm B: If Path CR/near CR, then 1 yr adjuvant nivo

### Metastatic 1st Line Trials

**UPC05618**
- **PI:** Dr. Tara Mitchell
- **Study Team:** PCAM; Valley Forge; Lancaster General Health; Huntsman Cancer Institute
- **Key Eligibility & Screening:**
  - Unresectable stage III or IV melanoma
  - ≥ 1 measurable site of disease by RECIST v.1.1 not previously irradiated
  - Allowed for refractory pts per 3:2:4
  - ≥ 3 months post gamma knife, surgery or stable 2 months post whole brain RT
  - Stable corticosteroid dose ≥ 1 month or tapering off and reached 20 mg prednisone or equivalent
- **Treatment Arms:**
  - Arm I: Nivo + HCQ; pts must be αPD-1 refractory
  - Arm II: Nivo + relatlimab; pts must be αPD-1 refractory

**UPC05620**
- **PI:** Dr. Ravi Amarawdi
- **Study Team:** PCAM
- **Key Eligibility & Screening:**
  - Metastatic 1st/2nd Line Trials
  - Unresectable stage III or IV melanoma
  - ≥ 1 measurable site of disease by RECIST v.1.1 not previously irradiated
  - Allowed for refractory pts per 3:2:4
  - ≥ 3 months post gamma knife, surgery or stable 2 months post whole brain RT
  - Stable corticosteroid dose ≥ 1 month or tapering off and reached 20 mg prednisone or equivalent
- **Treatment Arms:**
  - Phase Ib: Nivo + ipi + HCQ; pts must be αPD-1 refractory
  - Phase II: Nivo + relatlimab; pts must be αPD-1 refractory